Rituxan trials

Rituxan Rituximab is a monoclonal antibody indicated for treating advanced follicular lymphoma. The drug received EU approval in June It is being sold under the trade name MabThera. On 28 January , the US FDA approved Rituxan as a maintenance treatment for advanced follicular lymphoma patients who responded to initial treatment with Rituxan plus chemotherapy. The European Commission approved the drug for similar indication in October Rituxan is marketed in the US by Genentech and Biogen.

In Japan it is marketed by Chugai and Zenyaku Kogyo. Roche markets the drug in the rest of the world. NHL is a type of cancer of the white blood cells. The median survival of the disease-affected person is eight to ten years. It is estimated that follicular lymphoma is found in every one out of 3, people worldwide. The disease affects about , people worldwide every year.

As a therapeutic antibody, Rituxuan targets follicular lymphoma by binding to the antigen CD20 which is present on the surface of the normal or cancerous B-cells.

The trials were conducted between December and May The study enrolled 1, follicular lymphoma patients. It was an open label, multicentre and randomised study with two treatment phases. The study evaluated the safety and efficacy of Rituxan combined with chemotherapy in treating follicular lymphoma patients. MedlinePlus Information on Rituximab - A lay language summary of important information about this drug that may include the following:.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug.

However, much of the information may also apply to unapproved uses that are being studied. Targeted Cancer Therapies. Monoclonal Antibodies. Menu Contact Dictionary Search. Understanding Cancer.

What Is Cancer? Cancer Statistics. Cancer Disparities. Cancer Causes and Prevention. Risk Factors. Cancer Prevention Overview. Cancer Screening Overview.

Screening Tests. Diagnosis and Staging. Questions to Ask about Your Diagnosis. Types of Cancer Treatment. Side Effects of Cancer Treatment. Clinical Trials Information. A to Z List of Cancer Drugs. Questions to Ask about Your Treatment. Feelings and Cancer. Adjusting to Cancer. Day-to-Day Life. Support for Caregivers.

Questions to Ask About Cancer. Choices for Care. Talking to Others about Your Advanced Cancer. Planning for Advanced Cancer. Advanced Cancer and Caregivers. Questions to Ask about Advanced Cancer. Managing Cancer Care.

Finding Health Care Services. Advance Directives. Using Trusted Resources. Adolescents and Young Adults with Cancer. Emotional Support for Young People with Cancer. Cancers by Body Location. Late Effects of Childhood Cancer Treatment. Pediatric Supportive Care. Rare Cancers of Childhood Treatment. Childhood Cancer Genomics. Study Findings. Metastatic Cancer Research. Intramural Research. Extramural Research.

Cancer Research Workforce. Partners in Cancer Research. What Are Cancer Research Studies. Research Studies. Get Involved. Cancer Biology Research. Cancer Genomics Research. Research on Causes of Cancer. Cancer Prevention Research. Cancer Treatment Research. Cancer Health Disparities. Childhood Cancers Research. Global Cancer Research. Cancer Research Infrastructure. Clinical Trials. Frederick National Laboratory for Cancer Research. Bioinformatics, Big Data, and Cancer.

Annual Report to the Nation. Research Advances by Cancer Type. Stories of Discovery. Milestones in Cancer Research and Discovery. Biomedical Citizen Science. Director's Message. Budget Proposal. Stories of Cancer Research. Driving Discovery. Highlighted Scientific Opportunities. Research Grants. Research Funding Opportunities.

Cancer Grand Challenges. Research Program Contacts. Funding Strategy. Grants Policies and Process.